Search Clinical Trials in the European Union

Duration
Visits
Phase
Injection
Benefits
Drugs
Locations
Clinical Specialty
921-940 of 2,120 trials

ARO-DUX4 for Facioscapulohumeral Muscular Dystrophy Type 1

We are studying a new treatment for adults with Facioscapulohumeral Muscular Dystrophy Type 1 to see how safe it is and how it works in the body. This trial will help us understand its effects with different doses.

Facioscapulohumeral Muscular Dystrophy1-2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementInternal MedicineNeurology

Nephrotic Syndrome: Rituximab Treatment Comparison

We are comparing two Rituximab treatment plans for adults with relapsing nephrotic syndrome. The goal is to find out which regimen better prevents relapses and improves quality of life.

Nephrotic Syndrome1-2 yearsConfirmation phase (III)No PlaceboStandard MedicinesHematologyNephrology

Severe von Willebrand Disease: New Treatment Study

We are testing a new treatment for children with severe von Willebrand Disease to see if it helps control bleeding episodes and is safe during surgeries. The study will compare this treatment with and without an existing medication.

Von Willebrand's Factor Deficiency>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementHematologyPediatrics

Metastatic Colorectal Cancer: Sacituzumab Govitecan Study

We are investigating a new treatment for patients with metastatic colorectal cancer who have not responded to standard care. The study aims to see if this new drug can improve survival and response rates compared to existing treatments.

Metastatic Colorectal CancerEfficacy phase (II)Confirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesGastroenterologyOncology

Ulcerative Colitis in Kids: Vedolizumab vs. Infliximab

We are comparing the safety and effectiveness of a new treatment, vedolizumab, with the standard treatment, infliximab, for children aged 6-17 with ulcerative colitis. This study aims to find out which treatment works better for young patients.

Ulcerative Colitis3-6 monthsEfficacy phase (II)No PlaceboStandard MedicinesCost ReimbursementGastroenterologyPediatrics

Pain Management in Heart Surgery: Interpectoral-Pectoserratus Block

We are studying a new pain relief technique for patients undergoing minimally invasive aortic valve replacement. The goal is to see if it improves pain control and recovery compared to a standard approach.

Aortic Valve Disease>2 yearsMonitoring phase (IV)6-10 visitsStandard MedicinesCardiologyOtolaryngology

Localized Prostate Cancer: Darolutamide and Radiation Therapy

We are studying the effects of darolutamide with or without radiation therapy in patients with localized prostate cancer at high risk of relapse. The goal is to see if this combination improves survival and quality of life.

Localized Prostate Cancer>2 yearsConfirmation phase (III)11-15 visitsNo PlaceboInvestigational MedicinesOncology

Non-Small Cell Lung Cancer: Cemiplimab with Chemotherapy

We are studying whether adding new cancer treatments to cemiplimab and chemotherapy helps patients with operable non-small cell lung cancer. This trial aims to evaluate the effectiveness and safety of these combined treatments.

Non-Small Cell Lung CancerEfficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteOncologyPulmonology

Early Alzheimer's Disease: Sabirnetug Infusions

We are studying whether intravenous sabirnetug can slow cognitive decline in people with early Alzheimer's disease compared to a placebo. This trial aims to find new ways to help manage symptoms and improve quality of life.

Early Alzheimer's Disease1-2 yearsEfficacy phase (II)16-20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementNeurology

Childhood Leukemia: Inotuzumab Ozogamicin vs. ALLR3

We are studying whether Inotuzumab Ozogamicin works better than standard treatment for children with high-risk first relapse B-cell leukemia. The trial focuses on safety and long-term effectiveness in young patients.

Acute Lymphoblastic Leukemia6-12 monthsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementHematologyPediatrics

De-escalating Treatment for HER2-Positive Metastatic Breast Cancer

We are studying whether reducing treatment is safe for patients with undetectable cancer levels after long-term therapy. This trial aims to assess the impact on survival and quality of life.

HER2-Positive Breast Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Oligometastatic Colorectal Cancer: OPTIMISE Study

We are exploring whether a blood test can help decide the best treatment for patients with oligometastatic colorectal cancer. The study also looks at how this approach affects quality of life and treatment costs.

Colorectal Cancer with MetastasisEfficacy phase (II)No PlaceboStandard MedicinesOncology

Chronic Rhinosinusitis with Nasal Polyps: Dupilumab Study

We are exploring how Dupilumab may improve nasal barrier function in patients with Chronic Rhinosinusitis with nasal polyps. This study compares the effects of treatment on nasal cells from patients and healthy controls.

Chronic Rhinosinusitis with Nasal PolypsChronic Rhinosinusitis without Nasal Polyps>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesAllergologyOtolaryngology

Testosterone Supplementation for Obese Men with Type 2 Diabetes

We are studying whether intramuscular testosterone can reduce liver fat in obese men with low testosterone and type 2 diabetes. This trial will also look at the long-term effects on metabolic health.

HypogonadismType 2 Diabetes Mellitus (T2DM)Prediabetes>2 yearsMonitoring phase (IV)Post-Trial Drug AccessInvestigational MedicinesDiabetologyEndocrinologyInternal Medicine

Metastatic Non-Small Cell Lung Cancer: Zimberelimab and Domvanalimab Study

We are comparing a new treatment combination with chemotherapy to standard treatment for patients with untreated metastatic non-small cell lung cancer. This study aims to see which option may help improve survival and response rates.

Metastatic Non–Small Cell Lung CancerConfirmation phase (III)11-15 visitsNo PlaceboInvestigational MedicinesPartially RemoteOncology

Diabetic Macular Edema: Faricimab Treatment Study

We are exploring whether Faricimab can improve vision in patients with diabetic macular edema. The study also examines changes in eye health and treatment frequency over 12 months.

Diabetic Macular Edema>2 yearsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesEndocrinologyOphthalmology

Advanced Solid Tumors: BI-1206 with Pembrolizumab

We are studying a new treatment combining BI-1206 and pembrolizumab for patients with advanced solid tumors. This trial aims to find a safe dose and understand how well this combination works for those with specific types of cancer.

Malignant Solid Tumor>2 yearsSafety phase (I)Efficacy phase (II)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementInternal MedicineOncology

Advanced Cancers: BI-1808 Monoclonal Antibody

We are studying a new treatment called BI-1808 for people with advanced cancers, both alone and with pembrolizumab. The goal is to assess its safety and how well it is tolerated by patients.

Malignant Solid Tumor>2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesOncology

Colon Cancer: Personalized Treatment Strategy

We are exploring whether a blood-based genomic approach can improve outcomes for patients with operable Stage III and high-risk Stage II colon cancer compared to standard chemotherapy. This study also looks at side effects and quality of life.

Colorectal Cancer>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesInternal MedicineOncology

Multiple Myeloma: Mezigdomide vs. Pomalidomide

We are studying whether a new drug, mezigdomide, combined with bortezomib and dexamethasone, is more effective than pomalidomide with the same drugs for patients with relapsed or refractory multiple myeloma.

Relapsed or Refractory Multiple Myeloma≤3 monthsConfirmation phase (III)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementHematologyOncology